Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639090 | 0.91 | KMT2A (0.50) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL14957217 | 0.91 | KMT2A (0.50) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL14761328 | 0.91 | KMT2A (0.50) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL30963634 | 0.91 | KMT2A (0.50) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL23743060 | 0.88 | KMT2A (0.47) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL30150322 | 0.88 | KMT2A (0.47) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL22636287 | 0.88 | KMT2A (0.47) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL22636286 | 0.88 | KMT2A (0.47) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL31681813 | 0.88 | KMT2A (0.47) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL6752346 | 0.87 | KMT2A (0.46) | MDM4TP53CASP3KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1362042-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002057249-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | MDM4 4820/4885TP53 3988/4885CASP3 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.